Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam for PONV Prevention in High-Risk Patients
NCT04861337Phase 4Completed
- Sponsor
- Peking University First Hospital
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Remimazolam Group with Placebo Group (2 arms). Primary endpoint: Incidence of postoperative nausea and vomiting within 24 hours following surgery. Started May 2021; status: completed.
02
Drugs
remimazolam
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT04861337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861337.